arrow
K

Krzysztof Kamiński

collegium medicum jagiellonian university
H指数:25
被引数:1,627

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice

SSR504734(一种选择性甘氨酸转运体1型抑制剂)与抗惊厥药物之间的相互作用:小鼠的药效学和药代动力学研究

2026-09-290
PRE
Novel 3-Methoxypropanamide Derivatives as Potential Antiseizure and Antinociceptive Agents: Experimental Evidence from In Vitro and In Vivo Studies

新型3-甲氧基丙酰胺衍生物作为潜在的抗惊厥和镇痛剂:体外和体内研究的实验证据

2026-05-010
PRE
Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models

发现具有显著抗惊厥和镇痛作用的全新杂环吡咯烷-2-酮衍生物,在临床前模型中展现出效果。

2025-11-010
OAAI
Novel Dual 5-HT7 Antagonists and Sodium Channel Inhibitors as Potential Therapeutic Agents with Antidepressant and Anxiolytic Activities

新型双5-HT7拮抗剂和钠通道抑制剂作为具有抗抑郁和抗焦虑活性的潜在治疗药物

2025-10-020
OAAI
Effect of SSR504734, a Selective Glycine Transporter Type 1 Inhibitor, on Seizure Thresholds, Neurotransmitter Levels, and Inflammatory Markers in Mice

SSR504734(一种选择性甘氨酸转运体1型抑制剂)对小鼠惊厥阈值、神经递质水平和炎症标志物的影响

2025-02-260
OA
Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson's disease and its comorbidities
2025-02-010
PRE
Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates
2024-08-211
OAAI
Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies-In Vitro and In Vivo Characterization
2024-05-141
OAAI
Discovery of (R)-N-Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a Novel Orally Bioavailable EAAT2 Modulator with Drug- like Properties and Potent Antiseizure Activity In Vivo
2022-08-1914
OAAI